Concepedia

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

Alexander Pohl, Anthony B. El-Khoueiry, Dongyun Yang, W Zhang, Georg Lurje, Thomas Winder, S Hu-Lieskoven, Shabnoor Iqbal, Kathleen D. Danenberg, Michael Kahn,

The Pharmacogenomics Journal · 2012 · 44 citations · 26 references

DOI

Concepts

References

26

Prospective identification of tumorigenic breast cancer cells

Muhammad Al‐Hajj, Max S. Wicha, Adalberto Benito‐Hernández et al. · Proceedings of the National Academy of Sciences · 2003 · 10.4K citations · Full text

, , +11

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

Catherine O′Brien, Aaron Pollett, Steven Gallinger et al. · Nature · 2006 · 4.1K citations

, , +11

Identification and expansion of human colon-cancer-initiating cells

Lucia Ricci‐Vitiani, Dario Lombardi, Emanuela Pilozzi et al. · Nature · 2006 · 4K citations

, , +12

Prospective Identification of Tumorigenic Prostate Cancer Stem Cells

Anne T. Collins, Paul A. Berry, Catherine Hyde et al. · Cancer Research · 2005 · 2.8K citations

, , +17

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G. Willett, Yves Boucher, Emmanuelle di Tomaso et al. · Nature Medicine · 2004 · 2K citations · Full text

, , +17